SCHEMBL13041791

SCHEMBL13041791

Cc1cc(F)cc(NC(=O)Nc2ccc(-c3cc(C4CC4)nc4c3c(N)nn4C)cc2)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 9/20 0.59
KIT P10721 9/20 0.59
BLK P51451 8/20 0.59
KDR P35968 14/20 0.48
FLT3 P36888 10/20 0.48
FLT1 P17948 9/20 0.47
FLT4 P35916 9/20 0.47
LCK P06239 7/20 0.47
LYN P07948 7/20 0.47
SRC P12931 5/20 0.47
ABL1 P00519 4/20 0.47
AURKB Q96GD4 6/20 0.46
AURKA O14965 5/20 0.46
ROCK2 O75116 5/20 0.46
FGFR1 P11362 5/20 0.46
RPS6KB1 P23443 5/20 0.46
RPS6KA3 P51812 5/20 0.46
ROCK1 Q13464 5/20 0.46
DYRK3 O43781 4/20 0.46
MAP4K4 O95819 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13041757 0.91 KIT (0.52) CSF1RKITBLKKDRFLT3
SCHEMBL13041781 0.90 KIT (0.58) CSF1RKITBLKKDRFLT3
SCHEMBL13041797 0.89 KDR (0.55) CSF1RKITBLKKDRFLT3
SCHEMBL13041803 0.89 KIT (0.48) CSF1RKITBLKKDRFLT3
SCHEMBL13041753 0.89 KDR (0.54) CSF1RKITBLKKDRFLT3
SCHEMBL13041780 0.88 KDR (0.64) CSF1RKITBLKKDRFLT3
SCHEMBL13041789 0.87 KDR (0.54) CSF1RKITBLKKDRFLT3
SCHEMBL13041762 0.87 KDR (0.56) CSF1RKITBLKKDRFLT3
SCHEMBL13041792 0.86 KDR (0.65) CSF1RKITBLKKDRFLT3
SCHEMBL13041755 0.86 CSF1R (0.53) CSF1RKITBLKKDRFLT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-7825114-B2 Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same BAYER SCHERING PHARMA AG (DE) 2010-11-02 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-01-15 US disclosed
WO-2007144202-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, THEIR PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-12-21 WO disclosed
EP-1867647-A1 Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them. Bayer Schering Pharma Aktiengesellschaft (DE) 2007-12-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018129-A1 SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME KDR, TIE1, TEK CSF1R 918/4885KIT 22/4885BLK 305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.